It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: loam
a reply to: DancedWithWolves
The whole thing is one big cluster f*.....
As I have said before, the time to respond was in March, when MSF said it was out of control. It took until toady, really if you think about it, for WHO and the CDC to publicly acknowledge the seriousness of the situation.
When flu season hits, we are going to hear all kinds of madness.
Yup, that train already left the station.
When we started thinking about delivery systems, the one that I began focusing on about eight years ago was bananas. When you start peeling a banana, the minute that peeling comes off, you are exposing a sterile environment inside. There are no bacteria. There are no fungi in there. This is a self-contained sterile container that also contains protein. So you can think of it as a sterile protein-manufacturing system. If we can put genes into bananas and cause them to produce the protein we want--in this case, a vaccine--in that sterile compartment, then all we have to do is pop it open and deliver it.
For decades biotech companies have produced such antibodies by growing genetically engineered mouse cells in enormous metal bioreactors. But in the case of the new Ebola treatment ZMapp, developed by Mapp Pharmaceuticals, the antibodies were produced in tobacco plants at Kentucky Bioprocessing, a unit of tobacco giant Reynolds American.
The tobacco-plant-produced monoclonals have been dubbed “plantibodies.”
“Tobacco makes for a good vehicle to express the antibodies because it is inexpensive and it can produce a lot,” said Erica Ollmann Saphire, a professor at The Scripps Research Institute and a prominent researcher in viral hemorrhagic fever diseases like Ebola. “It is grown in a greenhouse and you can manufacture kilograms of the materials. It is much less expensive than cell culture.”
In the standard method of genetic engineering, DNA is slipped into bacteria, and the microbes produce a protein that can be used to combat a disease.
Did the NIH play a role in getting the experimental therapy to the two U.S. patients in Liberia?
This experimental treatment was arranged privately by Samaritan's Purse, the private humanitarian organization, which employed one of the Americans who contracted the virus in Liberia. Samaritan's Purse contacted the Centers for Disease Control and Prevention (CDC), who referred them to the National Institutes of Health (NIH). NIH was able to provide the organization with the appropriate contacts at the private company developing this treatment. The NIH was not involved with procuring, transporting, approving, or administering the experimental treatments.
Is ZMapp a vaccine?
No. ZMapp is being developed as a therapeutic product for treatment of people infected with Ebola virus, but not to prevent infection in the same manner as a vaccine. The best way to prevent infection currently is with stringent infection control measures.
There are currently no FDA approved vaccines for Ebola. The NIH's National Institute of Allergy and Infectious Diseases is working on developing an Ebola vaccine. NIH recently announced they are expediting their work, and aiming to launch phase 1 clinical trials of an Ebola vaccine in the fall. NIH is also supporting the Crucell biopharmaceutical company in its development of an Ebola/Marburg vaccine as well as Profectus Biosciences in its development of an Ebola vaccine.
Is the U.S. government involved in the development of ZMapp?
Two other companies, Tekmira and Biocryst Pharmaceuticals, receive funding from the Department of Defense's Defense Threat Reduction Agency and have therapeutic candidates for Ebola in early development. The Department of Defense is working with a company called Newlink to develop an Ebola vaccine candidate. BioCryst, with NIH support, is working to develop an antiviral drug to treat Ebola virus that is expected to begin Phase 1 testing later this year.
Since inception, Tekmira has fostered collaborations and partnerships with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company, the United States Government's Transformational Medical Technologies (TMT) Program, Monsanto, and other undisclosed pharmaceutical and biotechnology companies.
In 2014, Tekmira signed an Option Agreement with Monsanto, permitting Monsanto to obtain a license to use Tekmira's proprietary delivery technology. The companies' agreement and research collaboration will focus on the development of new innovative biological solutions for farmers, which have the potential to provide new options for sustainable pest, virus and weed control. The potential value of the transaction could reach up to $86.2 million following the successful completion of milestones.
Tuskegee University says it was in contact with parties at the national and international level to help expedite arrangements for the students to leave. While there, the students remain in a safe location and are being supported by local program affiliates, the university said.
originally posted by: Hellas
The first Ebola patient arriving in Spain
That's how Europe handles this